|View printer-friendly version|
- Expanded Exclusive, Global License to RPE and Photoreceptor Cells for Use in All Eye Disorders
- Data Presented at
International Society for Stem Cell Research (ISSCR) Conference
- Translational Vision Sciences & Technology (TVST) Journal Publishes OpRegen® Data
- Signing a new and expanded licensing agreement with
Hadassah Medical Organization of Jerusalem, Israel
- Presentation of data from its Phase 1/2a Dose Escalation Study of OpRegen® at ISSCR
- Presentation of the similarities between human retinal tissue and 3D retinal tissue derived using BioTime’s proprietary methodology and pluripotent cells at ISSCR
- Publication of preclinical data forming the foundation of the OpRegen® IND submission with the
U.S. Food & Drug Administrationin TVST
- Complete control of OpRegen® development program through consolidation of ownership in Cell Cure NeuroSciences
“OpRegen is making great progress in the clinic,” said
A poster demonstrating similarities between normal human retinal tissue and laboratory grown 3D retinal tissue derived using BioTime’s proprietary methodology with pluripotent cells (hPSC) was presented during ISSCR. The study compared normal human retinal cells with the BioTime’s proprietary hPSC-derived 3D retinal tissue for the potential use in helping to restore vision for blind people with advanced stages of retinal degeneration. The results presented demonstrated high correlation in gene expression profiles, between the various cellular components of normal human retinal tissue and the hPSC-derived tissue, including retinal pigment epithelium, retinal progenitor, photoreceptor, amacrine and ganglion cells.
In addition, the most recent data from the ongoing Phase I/II clinical trial of the lead product, OpRegen®, for the treatment of dry age-related macular degeneration was presented during the conference. The Phase I/IIa dose-escalation study evaluating the safety and efficacy of three different dose regimens of the company’s investigational product, OpRegen®. OpRegen® has received Fast Track designation from the
TVST Journal Publication
“These studies continue to leverage and expand our proprietary approaches utilizing hPSCs for a broad range of ocular diseases associated with cellular and tissue degeneration that other therapeutic approaches can’t address effectively,” said Oscar Cuzzani, M.D., Ph.D., BioTime’s Vice President of Clinical Development. “As ophthalmology remains among BioTime’s core areas of focus, we are uniquely positioned with our broad expertise, capabilities and IP portfolio in regenerative ophthalmology, creating a stronger pipeline to address problems of degenerative diseases of the eye.”
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for
To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn,
EVC Group, Inc.
Michael Polyviou, 646-445-4800
Doug Sherk, 646-445-4800
JQA Partners, Inc.
Jules Abraham, 917-885-7378